Biocom
Startups found with Biocom on the record. You apply on each company’s own site.
11
startups
162
open roles
Sorted by open roles
Xaira TherapeuticsSeries A · South San Francisco, CA, USAXaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research to better understand biology, expansive data generation t31 open rolesIambic TherapeuticsSan Diego, CaliforniaIambic Therapeutics hires through its own careers page.30 open roles
Vital BioSeries A · Ontario, CanadaVital was created to enable proactive, preventative, and accessible healthcare. We're starting with a radically disruptive approach to lab testing. Backed by many years of R&D by world-class scientists and engineers, we are a team of collaborators, re-engineering the nature of care delivery.21 open rolesRapport TherapeuticsSan Diego, CaliforniaRapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal 19 open roles
NewLimitSeries C · San Francisco, CA, USANewLimit is a biotechnology company that focuses on extending human healthspan through epigenetic reprogramming of cells. The company develops innovative medicines aimed at restoring youthful function in aging cells, targeting age-related diseases. NewLimit employs cutting-edge research to explore the potential of cellular rejuvenation, contributing to advancements in biomedicine. By utilizing epi17 open rolesVir BiotechnologySan Francisco, CaliforniaAt Vir Biotechnology, Inc., we leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in chronic hepatitis delta are complemented by strategic programs in oncology. Every day, we work with th16 open rolesInceptiveSeries A · ZürichBiological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers8 open rolesGordian BiotechnologyGrowth · South San Francisco, CaliforniaOur mission is to cure age-related disease by moving successful therapeutics toward clinical trials within months, not years. #CreatingTime7 open rolesMarea TherapeuticsSan Francisco, CaliforniaMarea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardio-endocrine diseases. The company’s lead program, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment 7 open roles
OctantSeries B · Emeryville, CaliforniaOctant is a well-backed team of experienced technologists and entrepreneurs navigating the complexity of biology and chemistry to develop next generation small molecules. Combining advanced cell engineering, high-throughput chemistry, and automation we are engineering best-in-class drugs across rare disease, oncology, and immunology.5 open rolesArda TherapeuticsSeries A · San Francisco Bay AreaArda Therapeutics is a seed-stage biotech taking aim at chronic diseases and aging by eliminating the pathological cells that drive these conditions. Our approach starts by using single-cell data to identify pathological cells and surface markers to target them. We then design therapies to eliminate these - and only these - cells. Arda is headquartered in the San Francisco Bay Area and backed by A1 open role